Compare BCE & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCE | UTHR |
|---|---|---|
| Founded | 1880 | 1996 |
| Country | Canada | United States |
| Employees | 40390 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3B | 23.9B |
| IPO Year | N/A | 1999 |
| Metric | BCE | UTHR |
|---|---|---|
| Price | $25.62 | $536.15 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 14 |
| Target Price | $29.50 | ★ $531.79 |
| AVG Volume (30 Days) | ★ 2.6M | 466.2K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | ★ 4.94% | N/A |
| EPS Growth | N/A | ★ 13.07 |
| EPS | N/A | ★ 27.86 |
| Revenue | N/A | ★ $1,483,300,000.00 |
| Revenue This Year | $3.80 | $7.77 |
| Revenue Next Year | $1.33 | $11.11 |
| P/E Ratio | ★ $5.19 | $19.12 |
| Revenue Growth | N/A | ★ 2.38 |
| 52 Week Low | $20.28 | $266.98 |
| 52 Week High | $26.52 | $548.12 |
| Indicator | BCE | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 46.38 | 61.74 |
| Support Level | $22.59 | $464.92 |
| Resistance Level | $26.02 | N/A |
| Average True Range (ATR) | 0.44 | 19.31 |
| MACD | -0.10 | 4.68 |
| Stochastic Oscillator | 2.55 | 85.60 |
BCE provides wireless, broadband, television, and landline phone services in Canada. It is one of the Big Three national wireless carriers, with over 10 million customers constituting about 30% of the market. It is also the incumbent local exchange carrier—the legacy telephone provider—throughout much of the eastern half of Canada, including in the most populous Canadian provinces: Ontario and Quebec. BCE has a media segment that holds television, radio, and digital media assets. BCE licenses the Canadian rights to HBO Max and Starz.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.